Faron Pharmaceuticals Oy
FPHAF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 108.93 | 0.73 | -0.22 | -1.74 |
| FCF Yield | -8.22% | -10.19% | -11.36% | -10.52% |
| EV / EBITDA | -15,415.02 | -8.50 | -7.84 | -10.21 |
| Quality | ||||
| ROIC | -0.30% | 2,475.56% | -978.10% | -319.24% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.89 | 0.77 | 0.80 | 1.05 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 3.06% | -2.36% | -3.02% | -28.78% |
| Safety | ||||
| Net Debt / EBITDA | -141.32 | -0.22 | -0.23 | 0.16 |
| Interest Coverage | -4.85 | 0.00 | -19.59 | -89.82 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |